View Post

Shigella Vaccine Candidate Awarded U.S. FDA Fast Track Designation

In COVID-19, Latest News by Precision Vaccinations

A seldom-discussed global health threat may soon have a U.S. Food and Drug Administration (FDA)- approved vaccine available.
Valneva SE and LimmaTech Biologics AG today announced that the U.S. FDA has granted Fast Track designation to Shigella4V (S4V), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate.

View Post

Approved Chikungunya Vaccine Confirmed Safe and Effective

In COVID-19, Latest News by Precision Vaccinations

As the winter season approaches in the United States, many people plan to vacation in the warmer weather of the Southern Hemisphere this year.
Since mosquitoes actively transmit various diseases in the Caribbean, Central, and South America, protecting yourself with a safe and effective vaccine one month before traveling south is an intelligent goal.

View Post

Shigella Vaccine Candidate Advancing in Clinical Trials

In COVID-19, Latest News by Precision Vaccinations

Shigella, the leading cause of diarrheal deaths worldwide, is having a resurgence in 2024. Among young children, it is estimated that diarrhea caused by Shigella is responsible for about 446,000 deaths globally each year.
In the United States, the Centers for Disease Control and Prevention (CDC) reported 16,498 Shigella cases on October 5, 2024 (Week 40), indicating an 8% increase from 2023. 
California (3,483), New York (2,478), and New Jersey (1,446) are leading other states.